MedTrace Logo

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

NCT05344248 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2022-12-08

No results posted yet for this study

Summary

JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A monoclonal antibody) Injection in patients with moderate to severe psoriasis.

Conditions

  • Moderate to Severe Psoriasis

Interventions

BIOLOGICAL

JS005 (recombinant humanized monoclonal antibody against IL-17A)

Subcutaneous injection

BIOLOGICAL

JS005 placebo

Subcutaneous injection

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2022-10-28
Completion
2022-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05344248 on ClinicalTrials.gov